Breaking Inflation unexpectedly fell in March, with core CPI tumbling to a 4-year low. Munich - Delayed Quote • EUR Illumina Inc (ILU.MU) Follow Compare 68.01 +0.30 +(0.44%) As of 2:49:30 PM GMT+2. Market Open. All News Press Releases SEC Filings Here's Why Illumina (ILMN) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. Argus cuts Illumina target, sees buying opportunity Argus lowered the firm’s price target on Illumina (ILMN) to $100 from $170 and keeps a Buy rating on the shares. The stock has fallen significantly over the past several months amid geopolitical tensions, antitrust issues, and slowing product sales, the analyst tells investors in a research note. However, the firm believes Illumina “appears to be turning the corner,” delivering multiple quarters of margin growth, launching new products and services, and providing “strong” earnings guidance for 2 3 Mid-Cap Stocks Walking a Fine Line Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo. How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern. Cintas, UPS, Illumina: Market Minute Here are some of the stocks on the move on Tuesday, March 25. Cintas (CTAS) has ended discussions about acquiring UniFirst (UNF). Shares of UPS (UPS) are slipping following a Bank of America note warning about its first quarter earnings. Illumina (ILMN) is adding some new faces to its board of directors. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. Activist Investor Meister to Join Illumina’s Board Activist investor Keith Meister will join the board of directors of troubled gene-sequencing maker Illumina and current board member Scott Gottlieb will become chairman. The moves, which the company announced Tuesday after The Wall Street Journal reported they were coming, will take effect Friday. Meister’s hedge fund, Corvex Management, first invested in Illumina in 2023 and has a stake of about 2.5% of the company’s shares, people familiar with the matter said. Illumina shares rise on WSJ report activist investor Meister will join board Investing.com -- Illumina shares rose over 2% premarket on Tuesday, following a Wall Street Journal report that activist investor Keith Meister would join the company’s board of directors. Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Holo Activist investor Keith Meister to join Illumina's board Illumina said on Tuesday activist investor Keith Meister would join the gene-sequencing maker's board and former U.S. Food and Drug Administration Commissioner Scott Gottlieb would take over as the company's chairman later this week. Illumina has been caught in the middle of a tariff war between the U.S. and China that has compelled it to cut its annual forecast and implement a cost-savings plan. China, which accounts for 7% of Illumina's sales, has banned imports of the company's genetic sequencers in response to U.S. President Donald Trump's additional 10% tariff on Chinese goods. Is Illumina, Inc. (ILMN) the Best Diagnostics Stock to Invest in Right Now? We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now. In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against the other best diagnostics stocks to invest in right now. Overview of the Clinical Diagnostics Market According to a report by Mordor […] Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain? ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes. Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative. Insights from the AGD database are being leveraged to accelerate drug target discovery, therapeutic research and clinical development. Why Illumina (ILMN) is a Top Value Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. Illumina, Inc. (ILMN): Among the Best Biotech Stocks to Buy According to Billionaires We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies could […] Jim Cramer on Illumina (ILMN): ‘A Challenged Company’ That He Doesn’t Prefer We recently published a list of Jim Cramer’s Latest Lightning Round: 7 Stocks in Focus. In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against other stocks that Jim Cramer discusses in latest lightning round. On Thursday, Jim Cramer, the host of Mad Money, pointed out that the […] JAZZ or ILMN: Which Is the Better Value Stock Right Now? JAZZ vs. ILMN: Which Stock Is the Better Value Option? Stocks to Watch Tuesday: Tesla, Southwest, Oracle, Illumina ↘️ Oracle (ORCL): The cloud-services company offered an upbeat sales outlook, but its quarterly results missed expectations. The stock dropped roughly 5.5% Tuesday morning. ↘️ Delta Air Lines (DAL): The carrier cut its outlook, as did American Airlines (AAL) and JetBlue (JBLU). Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego-based Illumina is lowering its 2025 guidance to $4.50 adjusted earnings per share, at the low end of the range of $4.50 to $4.65 a share given last month, Chief Financial Officer Ankur Dhingra told The Wall Street Journal on Monday. The moves will help the company offset the impact from China sanctions, Dhingra said. Illumina lowers outlook due to China sales ban, to cut $100 million in costs The company added that the cost savings would mitigate the impact of a potential reduction in revenue and related operating income from the company's Greater China business. "Our new fiscal 2025 guidance provides for limited further earnings contribution from China, and assumes a continuation of the macro trends we see today," said CFO Ankur Dhingra. China announced a ban on imports of genetic sequencers from Illumina that took effect from March 4, just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect. Performance Overview Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) Return ILU.MU S&P 500 (^GSPC) YTD -46.69% -9.46% 1-Year -44.34% +3.19% 3-Year -79.75% +18.65%